Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079404 · ClinicalTrials.gov registry record · Phase 1
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00079404 is a Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 58-participant average among 19 other Secondary Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00079404, a Phase 1 study of Secondary Acute Myeloid Leukemia and Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia. Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop cancer cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG tanespimycin
Study Locations (1)
California
- COG Phase I Consortium - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079404
The ClinicalTrials.gov registry entry for NCT00079404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 19 other Secondary Acute Myeloid Leukemia trials with a reported enrollment target (38% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Secondary Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which tanespimycin is the first listed.
NCT00079404 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00079404 about?
NCT00079404 is a clinical study titled "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia". This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia. Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop canc...
What is the current status of trial NCT00079404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-03.
What conditions does trial NCT00079404 study?
This clinical trial studies the following conditions: Secondary Acute Myeloid Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific, Recurrent Childhood Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Recurrent Childhood Acute Myeloid Leukemia.
What interventions are being tested in trial NCT00079404?
The interventions under investigation include: tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00079404?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00079404 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
ACTIVE NOT RECRUITING · Phase 1
-
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Secondary Acute Myeloid Leukemia
All registered trials for this condition
Unspecified Childhood Solid Tumor, Protocol Specific
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.